You are here

  • Home
  • Archive
  • Volume 70, Issue 9
  • Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study

Citation Tools

Article menu
Clinical and epidemiological research
Extended report
Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Burmester GR, Feist E, Sleeman MA, et al
Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
Annals of the Rheumatic Diseases 2011;70:1542-1549.